Tianda Pharmaceuticals Limited

455 KYG887471038

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:09 16/05/2024 pm IST			5-day change	1st Jan Change
0.246 ^HKD	0.00%		-7.17%	+12.84%

01:01pm	Tianda Pharmaceuticals Unit Gets Registration Go-Ahead for Acute Coronary Drug from Chinese Regulator	MT
26/03	Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	CI

Tianda Pharmaceuticals Limited entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

August 01, 2023

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million on August 1, 2023.

Latest news about Tianda Pharmaceuticals Limited

Tianda Pharmaceuticals Unit Gets Registration Go-Ahead for Acute Coronary Drug from Chinese Regulator	04:31pm	MT
Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	26/03	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Current Year from 1 January 2023 to 31 December 2023	21/03	CI
Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023	28/23/28	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Tianda Pharmaceuticals to Shrink H1 Loss by Over 70%	24/23/24	MT
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023	23/23/23	CI
Tianda Unit Buys Out 45% Stake in Meng Sheng Pharmaceutical	02/23/02	MT
Tianda Pharmaceuticals Limited entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.	01/23/01	CI
Tianda Pharmaceuticals Limited Announces Board Changes	27/23/27	CI
Tianda Pharmaceuticals Limited Approves Final Dividend	27/23/27	CI
Tianda Pharmaceuticals Limited Proposes Final Dividend for the Nine Months Ended 31 December 2022, Payable on or Before, 14 July 2023	19/23/19	CI
Tianda Pharmaceuticals Unit to Invest HK$10 Million in Fund	19/23/19	MT
Beijing Tong Ren Tang Chinese Medicine’s CEO Redesignated; New CEO Named	19/23/19	MT
Tianda Pharmaceuticals Limited Announces Final Ordinary Dividend for the Nine Months Ended 31 December 2023	23/23/23	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23/23/23	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23/23/23	CI
Tianda Pharmaceuticals Warns of Higher Loss in Fiscal Nine-Month Period; Shares Tumble 9%	20/23/20	MT
Tianda Pharmaceuticals Limited Provides Group Earnings Guidance for the Nine Months Period from April 1, 2022 to December 31, 2022	19/23/19	CI
Tianda Pharmaceuticals to Set Up Additional Production Line to Meet Rising Medicine Demand	19/22/19	MT
Tianda Pharmaceuticals' Loss for Half Year Through September Narrows	28/22/28	MT
Tianda Pharmaceuticals Limited Announces Changes in Financial Year End Date	25/22/25	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022	25/22/25	CI
Tianda Pharmaceuticals Chairman Buys 1.9 Million Shares; Stock Rises 3%	28/22/28	MT

Chart Tianda Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Tianda Pharmaceuticals Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The Company operates businesses in Hong Kong, China and Australia.

Sector

Pharmaceuticals

Calendar

26/06/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIANDA PHARMACEUTICALS LIMITED	+12.84%	6.77Cr
ELI LILLY AND COMPANY	+33.23%	71TCr
NOVO NORDISK A/S	+30.77%	60TCr
JOHNSON & JOHNSON	-2.09%	37TCr
MERCK & CO., INC.	+20.13%	33TCr
ABBVIE INC.	+5.32%	29TCr
ASTRAZENECA PLC	+14.77%	24TCr
NOVARTIS AG	+9.13%	21TCr
ROCHE HOLDING AG	-3.97%	20TCr
AMGEN INC.	+9.03%	17TCr

Other Pharmaceuticals